Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven

OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Yosprala Approval

<< Previous

Bullboard Posts

Next >>

Comment by kuatoliveson Aug 09, 2016 11:27am

104 Views

Post# 25122688

RE:Yosprala Approval

My thoughts are we'd be rich if Harris hadn't sold out Tribute shareholders the way he did. Thanks again Rob you putz. Tribute earnings continue to be strong and continue to grow. It'll be hard for me to let this go as I knew the merger was a bad idea. ANYWAY, it looks like revenue is now growing and losses narrowing, so we're moving in the right direction. Once yospralla gets approved, the growth will be appreciable. I think by this time next year we will have recovered much of the losses from 2015-2016. If ARLZ can triple its market cap in a reasonable amount of time, an ARLZ Depomed merger could be on the table.

<< Previous

Bullboard Posts

Next >>

Arbor Metals unearths encouraging results in lithium exploration